244 related articles for article (PubMed ID: 34444562)
1. Bayesian Sequential Monitoring of Single-Arm Trials: A Comparison of Futility Rules Based on Binary Data.
Sambucini V
Int J Environ Res Public Health; 2021 Aug; 18(16):. PubMed ID: 34444562
[TBL] [Abstract][Full Text] [Related]
2. Monitoring futility and efficacy in phase II trials with Bayesian posterior distributions-A calibration approach.
Kopp-Schneider A; Wiesenfarth M; Witt R; Edelmann D; Witt O; Abel U
Biom J; 2019 May; 61(3):488-502. PubMed ID: 30175405
[TBL] [Abstract][Full Text] [Related]
3. Do we need to adjust for interim analyses in a Bayesian adaptive trial design?
Ryan EG; Brock K; Gates S; Slade D
BMC Med Res Methodol; 2020 Jun; 20(1):150. PubMed ID: 32522284
[TBL] [Abstract][Full Text] [Related]
4. Comparing Bayesian early stopping boundaries for phase II clinical trials.
Jiang L; Yan F; Thall PF; Huang X
Pharm Stat; 2020 Nov; 19(6):928-939. PubMed ID: 32720462
[TBL] [Abstract][Full Text] [Related]
5. A Bayesian hierarchical monitoring design for phase II cancer clinical trials: Incorporating information on response duration into monitoring rules.
Wang J; Ma J; Cai C; Daver N; Ning J
Stat Med; 2021 Sep; 40(21):4629-4639. PubMed ID: 34101217
[TBL] [Abstract][Full Text] [Related]
6. A randomized Bayesian optimal phase II design with binary endpoint.
Ding Y
J Biopharm Stat; 2023 Mar; 33(2):151-166. PubMed ID: 35793222
[TBL] [Abstract][Full Text] [Related]
7. An extension of Bayesian predictive sample size selection designs for monitoring efficacy and safety.
Teramukai S; Daimon T; Zohar S
Stat Med; 2015 Sep; 34(22):3029-39. PubMed ID: 26038148
[TBL] [Abstract][Full Text] [Related]
8. Bayesian and frequentist approaches to sequential monitoring for futility in oncology basket trials: A comparison of Simon's two-stage design and Bayesian predictive probability monitoring with information sharing across baskets.
Kaizer A; Zabor E; Nie L; Hobbs B
PLoS One; 2022; 17(8):e0272367. PubMed ID: 35917296
[TBL] [Abstract][Full Text] [Related]
9. Interpreting a Bayesian phase II futility clinical trial.
Beall J; Cassarly C; Martin R
Trials; 2022 Nov; 23(1):953. PubMed ID: 36414953
[TBL] [Abstract][Full Text] [Related]
10. Over-accrual in Bayesian adaptive trials with continuous futility stopping.
Barrado LG; Burzykowski T
Clin Trials; 2023 Jun; 20(3):252-260. PubMed ID: 36803007
[TBL] [Abstract][Full Text] [Related]
11. Optimality criteria for futility stopping boundaries for group sequential designs with a continuous endpoint.
Li X; Herrmann C; Rauch G
BMC Med Res Methodol; 2020 Nov; 20(1):274. PubMed ID: 33153438
[TBL] [Abstract][Full Text] [Related]
12. Interim futility analysis with intermediate endpoints.
Goldman B; LeBlanc M; Crowley J
Clin Trials; 2008; 5(1):14-22. PubMed ID: 18283075
[TBL] [Abstract][Full Text] [Related]
13. Bayesian group sequential designs for phase III emergency medicine trials: a case study using the PARAMEDIC2 trial.
Ryan EG; Stallard N; Lall R; Ji C; Perkins GD; Gates S
Trials; 2020 Jan; 21(1):84. PubMed ID: 31937351
[TBL] [Abstract][Full Text] [Related]
14. Adaptive treatment allocation and selection in multi-arm clinical trials: a Bayesian perspective.
Arjas E; Gasbarra D
BMC Med Res Methodol; 2022 Feb; 22(1):50. PubMed ID: 35184731
[TBL] [Abstract][Full Text] [Related]
15. Trial monitoring via a futility criterion for interim results on a count data endpoint and a continuous endpoint.
Quan H; Kang T; Fan C; Lu X; Chen X; Luo X; Wei L
Contemp Clin Trials; 2021 Apr; 103():106316. PubMed ID: 33571688
[TBL] [Abstract][Full Text] [Related]
16. Unified exact design with early stopping rules for single arm clinical trials with multiple endpoints.
Wei W; Esserman D; Kane M; Zelterman D
Stat Methods Med Res; 2021 Jul; 30(7):1575-1588. PubMed ID: 34159859
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of a multi-arm multi-stage Bayesian design for phase II drug selection trials - an example in hemato-oncology.
Jacob L; Uvarova M; Boulet S; Begaj I; Chevret S
BMC Med Res Methodol; 2016 Jun; 16():67. PubMed ID: 27250349
[TBL] [Abstract][Full Text] [Related]
18. Comparison of futility monitoring guidelines using completed phase III oncology trials.
Zhang Q; Freidlin B; Korn EL; Halabi S; Mandrekar S; Dignam JJ
Clin Trials; 2017 Feb; 14(1):48-58. PubMed ID: 27590208
[TBL] [Abstract][Full Text] [Related]
19. Futility interim monitoring with control of type I and II error probabilities using the interim Z-value or confidence limit.
Lachin JM
Clin Trials; 2009 Dec; 6(6):565-73. PubMed ID: 19933716
[TBL] [Abstract][Full Text] [Related]
20. Optimal timing for an accelerated interim futility analysis incorporating real world data.
Haine LMF; Murray TA; Koopmeiners JS
Contemp Clin Trials; 2024 May; 140():107489. PubMed ID: 38461938
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
